N-Acetyl Selank Amidate

Mechanism

A souped-up version of Selank, a Russian anti-anxiety peptide. The added chemical modifications (an acetyl cap on one end, an amide cap on the other) help it survive longer in your bloodstream and cross into the brain more easily. Users report calmer focus, reduced anxiety, and improved mood — often stronger and longer-lasting than regular Selank.

Effects

NERVOUS SYSTEM (ANXIOLYTIC): NA-Selank-Amidate is an enhanced version of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, a synthetic analog of the endogenous immunomodulatory peptide tuftsin). The N-acetyl modification protects against aminopeptidase degradation, and the C-terminal amide prevents carboxypeptidase cleavage — together these modifications extend half-life by 2-3x and improve blood-brain barrier (BBB) penetration [in vitro, pharmacokinetic modeling]. Anxiolytic mechanism: modulates GABAergic neurotransmission — enhances GABA-A receptor sensitivity without direct agonism (unlike benzodiazepines), meaning anxiolytic effect without sedation or dependence [animal — Selank data extrapolated]. Influences serotonin metabolism — alters expression of key serotonin-related genes (TPH2, SERT, 5-HT1A) in hippocampus and frontal cortex [animal]. Reduces enkephalinase activity, increasing endogenous enkephalin levels (endogenous opioid anxiolysis) [animal]. COGNITIVE: Enhances memory consolidation and retrieval — improved performance in passive avoidance and Morris water maze tests [animal]. Increases BDNF expression in hippocampus (neuroplasticity support) [animal]. Nootropic effects attributed to modulation of monoamine neurotransmitter balance [animal]. IMMUNE SYSTEM: Retains tuftsin's immunomodulatory properties — stimulates phagocytosis by monocytes and neutrophils, enhances NK cell activity, modulates cytokine production (shifts toward balanced Th1/Th2 response) [in vitro, animal, Russian clinical studies]. Antiviral properties — influences interferon-related gene expression (IL-6, IFN genes) [animal, in vitro]. This dual anxiolytic + immunomodulatory profile is unique — no other anxiolytic peptide has significant immune effects [review]. ANTI-INFLAMMATORY: Reduces neuroinflammation markers in brain tissue [animal]. Modulates expression of inflammatory cytokines centrally and peripherally [animal].

Practitioner Guide

ADMINISTRATION: Intranasal is the primary route — NA-Selank-Amidate crosses the BBB effectively via the nasal mucosa (olfactory and trigeminal nerve pathways). Subcutaneous injection is an alternative but intranasal is preferred for CNS effects. DOSING: Intranasal 200-600 mcg/day, typically divided into 2-3 doses. Start at 200 mcg/day (100 mcg each nostril, once daily) and titrate up based on response. Experienced users often settle at 300-400 mcg/day. Duration of effect per dose: 4-8 hours (vs. 2-4 hours for standard Selank — the enhanced modifications approximately double duration). Some practitioners recommend twice-daily dosing (morning + early afternoon) for sustained anxiolytic coverage. CYCLING: Common protocols: 5 days on/2 days off, or 3 weeks on/1 week off. Some users take daily without cycling for extended periods (months) without reported tolerance — the GABA-modulatory mechanism (not direct agonism) may explain the lack of tolerance/dependence. However, cycling is prudent given limited long-term data. STACKING: Frequently combined with NA-Semax-Amidate for a comprehensive nootropic/anxiolytic stack — Selank for anxiety and emotional stability, Semax for cognitive enhancement and BDNF elevation. Typical stack: NA-Selank-Amidate 300 mcg intranasal AM + NA-Semax-Amidate 300 mcg intranasal AM. Can add PE 22-28 for antidepressant support (theoretical synergy via different mechanisms). Other synergistic supplements: L-theanine (100-200mg — complementary GABAergic support), magnesium glycinate (300-600mg — GABA receptor cofactor), ashwagandha (300-600mg — HPA axis support). COMPARISON TO STANDARD SELANK: NA-Selank-Amidate is reported to be more potent and longer-lasting than standard Selank by the nootropic community. Estimated 2-3x duration of action per dose. Some users who did not respond to standard Selank report effects from the NA-Amidate form, possibly due to improved BBB penetration. SOURCING: Available from research peptide suppliers (e.g., Science.bio [now closed], Ceretropic [now closed], current sources vary). Quality varies — look for third-party testing (HPLC, mass spec). Typically supplied as lyophilized powder or reconstituted nasal spray. STORAGE: Lyophilized: stable at -20°C for years, room temperature for months. Reconstituted nasal spray: store at 2-8°C, use within 4-6 weeks. Bacteriostatic water for reconstitution. SAFETY PROFILE: Based on Selank clinical data (Russian regulatory approval) and community experience, side effect profile is very favorable — no sedation, no dependence, no cognitive impairment. Rare reports: mild nasal irritation (intranasal), transient headache. No known serious adverse effects, though human safety data for the NA-Amidate variant specifically is from community reports, not clinical trials. CONTRAINDICATIONS: Theoretical concern with autoimmune conditions (immunostimulatory properties). Caution with anticoagulants (tuftsin analogs can theoretically affect platelet function, though not clinically observed).

Evidence

• Functional Connectomic Approach to Studying Selank and Semax Effects

  Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF (2020) — Dokl Biol Sci — PMID: 32342318

  Selank and Semax both altered resting-state fMRI functional connectivity between right amygdala and temporal cortex within 20 minutes of intranasal administration in 52 healthy participants. Each peptide showed distinct connectivity patterns — Selank predominantly anxiolytic (amygdala-focused); Semax more prefrontal/executive (DLPFC). First direct neuroimaging evidence of distinct mechanisms.

  moderate

• GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells

  Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M (2017) — Front Pharmacol — PMID: 28293190

  Selank affects GABAergic system via modulation of GABA-receptor interactions rather than direct mRNA level changes. Combined Selank+GABA nearly completely suppressed GABA-induced gene expression changes, suggesting Selank modulates GABA receptor binding. Selank may enhance effects of olanzapine (antipsychotic) on GABAergic gene expression.

  moderate

• Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats

  Kasian A, Kolomin T, Andreeva L, Bondarenko E, Myasoedov N, Slominsky P, Shadrina M (2017) — Behav Neurol — PMID: 28280289

  In chronic mild stress conditions, Selank alone was most effective at reducing elevated anxiety. Selank+diazepam combination normalized anxiety levels fully to pre-stress baseline. Selank monotherapy produced less tolerance/rebound than diazepam alone. Supports anxiolytic efficacy comparable to benzodiazepines with potentially safer profile.

  moderate

• A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders

  Medvedev VE, Tereshchenko ON, Israelian AIu, Chobanu IK, Kost NV, Sokolov OIu, Miasoedov NF (2014) — Zh Nevrol Psikhiatr Im S S Korsakova — PMID: 25176261

  Selank demonstrated pronounced anxiolytic and mild nootropic effects in 60 patients with phobic-anxiety and somatoform disorders. Anxiolytic effect lasted one week after last dose. Positive impact on quality of life. Comparable efficacy to phenazepam (benzodiazepine) with better tolerability profile.

  moderate

Research Summary

TIER 1: No RCTs on NA-Selank-Amidate specifically. Selank (parent compound) has Russian regulatory approval (2009) for generalized anxiety disorder and neurasthenia, based on Russian Phase II/III trials showing anxiolytic efficacy comparable to medazepam (benzodiazepine) without sedation or dependence. However, these trials do not meet ICH-GCP standards and have not been replicated by Western groups. TIER 2: Preclinical studies on Selank: anxiolytic effects in multiple behavioral models (Seredenin et al., multiple publications). Gene expression studies — Selank modulates expression of 36 genes related to GABAergic, serotonergic, and immune pathways (Volkova et al., 2016). Reviews of tuftsin analogs and their immunomodulatory properties. Pharmacokinetic studies of modified Selank analogs (including N-acetyl and amide modifications) showing improved stability. TIER 3: Extensive nootropic community experience reports (Reddit r/nootropics, Longecity — hundreds of user reports over 5+ years). Russian clinical practitioner experience with Selank for anxiety, cognitive complaints, and immune support. International biohacking community documentation. Community consensus: one of the more reliable and well-tolerated nootropic peptides, with consistent anxiolytic effects. KEY FINDINGS: Selank is a genuinely unique molecule — an anxiolytic with immunomodulatory properties and no sedation/dependence liability. The Russian clinical approval provides some confidence, though evidence standards differ. NA-Selank-Amidate likely offers pharmacokinetic advantages (stability, BBB penetration) but has no independent clinical data. Community experience is extensive and generally positive. GAPS: No Western clinical trials for Selank or NA-Selank-Amidate. PK data for NA-Selank-Amidate in humans unknown. Optimal dosing not established. Long-term safety unstudied. Immune modulation effects not characterized in controlled human studies. ACTIVE TRIALS: None on ClinicalTrials.gov for NA-Selank-Amidate. Selank research continues at the Institute of Molecular Genetics, Russian Academy of Sciences.